Over half a million people die from cancer every year, according to current statistics. For those diagnosed with pancreatic cancer, the current five-year survival rate is 12% but for those diagnosed in metastatic stages, survival is less than 3%. A startup leveraging technology created at the University of Tennessee Health Science Center (UTHSC) is now (read more)
HSC Office
UTRF Celebrates Record Number of Licenses, Agreements, Patents at Annual Innovation Awards
This spring, the University of Tennessee Research Foundation was honored to recognize UT innovators from across the state at UTRF’s annual Innovation Awards. For the first time in two years, UTRF staff and valued partners gathered in Knoxville and Memphis to celebrate the innovation coming from the university. At the events, hosted at UT Knoxville (read more)
UTRF Licensee Veru, Inc. Announces Positive Results of COVID-19 Therapy’s Phase 3 Clinical Study, Seeking Emergency Use Authorization from FDA
UT Research Foundation licensee Veru, Inc. announced on April 11, 2022, that their Phase 3 clinical trial of sabizabulin as an oral therapy for hospitalized severe COVID-19 patients at high risk for Acute Respiratory Distress Syndrome (ARDS) and death showed the drug to be safe and effective. The trial was halted early due to the (read more)